Raghav Gupta, MD
Pulmonary Disease · Evansville, INNPI 1659668804
Payments from drug & device makers
Across 441 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Johnson & Johnson$2K
- AstraZeneca$2K
- Boehringer Ingelheim$976
- Mylan Specialty L.p.$577
- Insmed, Inc.$379
- plus $3K from 29 others
What the payments were for
- Travel & lodging$1,36514%
- Food & beverage$8,30685%
- Education$1221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 96 | $1,541 |
| Johnson & Johnson(2 entities) | 6 | $1,516 |
| AstraZeneca | 68 | $1,512 |
| Boehringer Ingelheim | 62 | $976 |
| Mylan Specialty L.p. | 27 | $577 |
| Insmed, Inc. | 24 | $379 |
| Sunovion Pharmaceuticals Inc. | 24 | $366 |
| Grifols USA, LLC | 16 | $314 |
| Blue Earth Diagnostics | 3 | $293 |
| Sanofi | 11 | $252 |
| Regeneron Healthcare Solutions, Inc. | 12 | $224 |
| Amgen | 9 | $219 |
| Electromed, Inc. | 13 | $199 |
| AbbVie(2 entities) | 11 | $169 |
| Viatris Specialty LLC | 6 | $163 |
| Actelion Pharmaceuticals US, Inc. | 8 | $158 |
| Travere Therapeutics, Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 5 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| CSL Behring | 4 | $99 |
| United Therapeutics Corporation | 4 | $94 |
| Merck | 5 | $79 |
| Pulmonx Corporation | 4 | $57 |
| Genentech USA, Inc. | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Coloplast | 2 | $31 |
| Pfizer | 2 | $28 |
| Astellas Pharma US Inc | 1 | $20 |
| Shionogi Inc | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Monaghan Medical Corporation | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Ambu Inc. | 1 | $15 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$1,365
- POSLUMA$261
- BREZTRI$208
- FASENRA$208
How this compares
$9,793 in reported general payments places this provider in the 75th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $669,308 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 859 | $666,882 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 435 | $349,795 |
| Breo ElliptaFluticasone/Vilanterol | 264 | $119,621 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 94 | $56,359 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 100 | $54,261 |
| Advair HfaFluticasone Propion/Salmeterol | 130 | $53,037 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 94 | $50,512 |
| Spiriva RespimatTiotropium Bromide | 83 | $49,144 |
| SymbicortBudesonide/Formoterol Fumarate | 90 | $28,725 |
| DuleraMometasone/Formoterol | 82 | $28,203 |
| Incruse ElliptaUmeclidinium Bromide | 73 | $26,494 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 236 | $23,348 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 90 | $13,366 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 29 | $13,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,541 | $876,3551,326 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Stiolto Respimat, Spiriva Respimat | $976 | $825,323320 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $1,512 | $387,308541 claims |
| MerckDulera | $79 | $28,20382 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $110 | $3,77614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Evansville
- Victor ChavezEvansville$52K
- Roger JohnsonEvansville$27K
- David RyonEvansville$16K
- Cynthia BrownIndianapolis$7.3M
- Imad ShawaGreenwood$1.4M
- David MaresAnderson$1.3M
- Raja DevanathanHobart$862K
- Olusegun ApataGary$780K
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.